---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094411"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2026-08-12T10:45:36+00:00"
generated_at: "2026-08-12T10:50:03.170087+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Liquidia posts Q2 2026 net income of $74.7M; YUTREPIA sales surge to $170.4M

## Summary
- YUTREPIA net sales $170.4M in Q2 2026, up 31% from Q1 2026; Q2 2025 product sales were $6.5M.
- Net income $74.7M ($0.84 basic / $0.74 diluted EPS) vs. net loss of $41.6M in Q2 2025.
- Adjusted EBITDA $96.3M; cash and equivalents $284.2M at June 30, 2026, up from $190.7M at year-end 2025.
- ~5,900 unique patient prescriptions and >5,000 patients started on YUTREPIA since June 2025 launch; >1,100 prescribers.
- Enrollment underway in Re-Spire, pivotal study for L606; 10 clinical studies progressing across known and new indications.

## SEC filing metadata
- accession: 0001104659-26-094411
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2026-08-12T10:45:36+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465926094411/0001104659-26-094411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465926094411/tm2622888d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094411
- JSON: https://secwatch.observer/filing/0001104659-26-094411.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.